Skip to content

A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease.

Chronic Obstructive Pulmonary Disease | COPD

We are doing this study to learn more about how safe and effective a new drug called AZD6793 is in treating COPD, reducing number of sudden COPD symptoms worsening (exacerbations) and also to better understand the disease and associated health problems. In addition, this study will help select the best effective and safe dose of AZD6793 to be used in subsequent clinical studies of participants with COPD.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    40 to 80

Participation Criteria

Inclusion Criteria:
Diagnosed with Moderate- very Severe COPD for at least 12 months

Current or Former Smoker of Tobacco

BMI within the range 18 to 44.9 kg/m2
(inclusive)
Exclusion Criteria:
Diagnosed with a different lung disease
Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neurological, endocrine, gastrointestinal, or pulmonary.
Currently using Oxygen over 4 LPM
Participants who have cancer that has not been in complete remission for at least 5 years.

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Hannah Anstruther

[email protected]
780 492 3741
Primary Contact

Angela Johnson

[email protected]
780 492 3741
Primary Contact

Amy May

[email protected]
780 492 3741
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00154451